H.C. Wainwright downgraded Innate Pharma (IPHA) to Neutral from Buy without a price target The company is prioritizing three assets, IP4502, lacutamab, and monalizumab, which do not have meaningful catalysts in the next 12 months, the analyst tells investors in a research note. The firm believes a “financing overhang is imminent” if Innate is unable to identify a partner for lacutamab development nor able monetize any of its assets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA:
- Innate Pharma SA Reports First Half 2025 Financial Results
- Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
- Innate Pharma downgraded to Market Perform from Outperform at Leerink
- Innate Pharma initiated with a Buy at BTIG
- Innate Pharma’s IPH4502 Study: A New Hope in Cancer Treatment